Integra Lifesciences Holdings Corporation · NASDAQ:IART
Integra Lifesciences — Merger or Acquisition (December 2022)
10 slides from Integra Lifesciences's merger presentation, Dec 1, 2022
Slide 1: Acquisition of Surgical Innovation Associates (SIA), Inc.
ACQUISTION OF SURGICAL INNOVATION ASSOCIATES (SIA), INC. DECEMBER 01, 2022 Confidential ‐ For internal use only
Slide 2: Legal Information: Forward-Looking Statements
Legal Information 2 Forward‐Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, othe
Slide 3: Non-GAAP Financial Measures
Non‐GAAP Financial Measures 3 This presentation includes anticipated changes to our adjusted earnings per diluted share, which is a non‐GAAP measure, in connection with the announced transaction. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributab
Slide 4: Acquisition overview & strategic rationale
Confidential – For Internal Use Only Acquisition overview & strategic rationale 4 Strategic Rationale SIA Business Description • Private company headquartered in Chicago, IL, founded in 2016 by plastic surgeons and entrepreneurs • Founded to commercialize resorbable synthetic mesh for use in plastic
Slide 5: Global breast reconstruction market represents attractive opportunity for surgical matrix business
Global breast reconstruction market represents attractive opportunity for surgical matrix business, historically dominated by human derived surgical matrices 5 Global Addressable Market 2021 Key Market Drivers Factors Driving U.S. Disruption • Insurance coverage influences reconstructive choices • G
Slide 6: Anticipated disruption in U.S. breast reconstruction landscape
Anticipated disruption in U.S. breast reconstruction landscape via shifting surgical techniques, value‐based care trends, and regulatory actions 6 IBBR procedures involving use of a surgical matrix Procedural Technique Sub‐Pectoral Pre‐Pectoral Currently no surgical matrices are FDA‐approved for imp
Slide 7: SurgiMend PRS collagen matrix targeting expanded-label market entry in 2024
SurgiMend PRS collagen matrix targeting expanded‐label market entry in 2024 7 With SurgiMend PRS, Integra is a leading contender today to capture opportunity in this market SurgiMend PRS Cost‐ Effective First to PMA* with Fewer Complications Strong, Flexible, Consistent Material • Acellular dermal m
Slide 8: DuraSorb monofilament mesh targeting expanded-label market entry in 2025/2026
DuraSorb monofilament mesh targeting expanded‐label market entry in 2025/2026 8 DuraSorb poised to become the clinical leader in the resorbable synthetic mesh category for IBBR DuraSorb Cost‐ Effective 2nd to PMA* with Pre + Sub Procedures Strong, Trusted Resorbable Material • Soft, warp‐knit monofi
Slide 9: Portfolio advantages: SurgiMend and DuraSorb
Portfolio Advantages • Expanded sales & marketing footprint • Strengthens contracting position across categories Commercial Synergy • Clinical advantages across a broader range of procedures • Enables delivery of cost‐effective solutions to distinct segments across varied sites of care Clinical & Co
Slide 10: SIA acquisition adds resorbable synthetic technology to Integra's capabilities
SIA acquisition adds resorbable synthetic technology to Integra’s strong capabilities in soft tissue reconstruction Highly strategic acquisition that advances our market leadership ambitions 10 Brings us closer to reaching our ambition of becoming a global leader in breast reconstruction with future
Integra LifeSciences Holdings — Merger or Acquisition (December 2022) on 6ix